PointofLaw.com
 Subscribe Subscribe   Find us on Twitter Follow POL on Twitter  
   
 
   

 

 

Pfizer pulls Bextra



Today, drug manufacturer Pfizer has pulled its pain medication Bextra from the market. Bextra is a COX-2 inhibitor, the same class of drug as Merck drug Vioxx, which was pulled last fall (and, more recently, approved for reintroduction). (For more on Vioxx, see Feb. 8, Jan. 27, Jan. 5, Dec. 31, Dec. 27, Dec. 18, Dec. 2, Nov. 18 (II), Nov. 18 (I), Nov. 8, Oct. 4). As lawyers are likely to pile on to this one, as well, expect a lot more to follow. (Note: unlike the Vioxx case, in which Merck pulled the drug without FDA prompting, the FDA ordered this decision, with which Pfizer has said it "respectfully disagrees.")

 

 


Rafael Mangual
Project Manager,
Legal Policy
rmangual@manhattan-institute.org

Katherine Lazarski
Manhattan Institute
klazarski@manhattan-institute.org

 

Published by the Manhattan Institute

The Manhattan Insitute's Center for Legal Policy.